Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, August 9, 2022
[ Tue, Aug 09th 2022
] - WOPRAI
[ Tue, Aug 09th 2022
] - WOPRAI
[ Tue, Aug 09th 2022
] - WOPRAI
[ Tue, Aug 09th 2022
] - WOPRAI
[ Tue, Aug 09th 2022
] - WOPRAI
[ Tue, Aug 09th 2022
] - WOPRAI
[ Tue, Aug 09th 2022
] - WOPRAI
[ Tue, Aug 09th 2022
] - WOPRAI
[ Tue, Aug 09th 2022
] - WOPRAI
[ Tue, Aug 09th 2022
] - WOPRAI
[ Tue, Aug 09th 2022
] - WOPRAI
[ Tue, Aug 09th 2022
] - WOPRAI
[ Tue, Aug 09th 2022
] - WOPRAI
[ Tue, Aug 09th 2022
] - WOPRAI
[ Tue, Aug 09th 2022
] - WOPRAI
[ Tue, Aug 09th 2022
] - WOPRAI
[ Tue, Aug 09th 2022
] - WOPRAI
[ Tue, Aug 09th 2022
] - WOPRAI
[ Tue, Aug 09th 2022
] - WOPRAI
[ Tue, Aug 09th 2022
] - WOPRAI
[ Tue, Aug 09th 2022
] - WOPRAI
[ Tue, Aug 09th 2022
] - WOPRAI
[ Tue, Aug 09th 2022
] - WOPRAI
[ Tue, Aug 09th 2022
] - WOPRAI
[ Tue, Aug 09th 2022
] - WOPRAI
[ Tue, Aug 09th 2022
] - WOPRAI
[ Tue, Aug 09th 2022
] - WOPRAI
[ Tue, Aug 09th 2022
] - WOPRAI
[ Tue, Aug 09th 2022
] - WOPRAI
Gregory Renza Maintained (ACAD) at Buy with Decreased Target to $21 on, Aug 9th, 2022
Gregory Renza of RBC Capital, Maintained "ACADIA Pharmaceuticals Inc." (ACAD) at Buy with Decreased Target from $26 to $21 on, Aug 9th, 2022.
Gregory has made no other calls on ACAD in the last 4 months.
There are 4 other peers that have a rating on ACAD. Out of the 4 peers that are also analyzing ACAD, 2 agree with Gregory's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Neena Bitritto-Garg of "Citigroup" Downgraded from Strong Buy to Hold and Decreased Target to $15 on, Monday, August 8th, 2022
- Jay Olson of "Oppenheimer" Maintained at Hold with Decreased Target to $19 on, Tuesday, June 21st, 2022
These are the ratings of the 2 analyists that currently disagree with Gregory
- Ritu Baral of "Cowen & Co." Maintained at Buy with Decreased Target to $21 on, Monday, August 8th, 2022
- Charles Duncan of "Cantor Fitzgerald" Maintained at Buy with Decreased Target to $26 on, Tuesday, June 21st, 2022
